Patrick Dallemagne

Professor CEx2

Université de Caen Normandie

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (12)

François-Xavier Toublet

Lecturer in organic and medicinal chemistry

Université de Limoges

FRANCE

View details

Jana Sopkova-de Oliveira Santos

Université de Caen Normandie

FRANCE

View details

hélène MARTIN

Université de Franche-Comté

FRANCE

View details

Lhassane Ismaili

Professeur

Université de Franche-Comté

FRANCE

View details

Serge Mignani

Full Professor

PORTUGAL

View details

Marc Since

Lecturer, Dr

FRANCE

View details

Krzysztof Jozwiak

Medical University of Lublin

POLAND

View details

Artur Wnorowski

Assistant Professor

Medical University of Lublin

POLAND

View details

Audrey DAVIS

Université de Caen Normandie

FRANCE

View details

Aurélie Malzert-Freon

Normandie Université

FRANCE

View details

thomas freret

Université de Caen Normandie

FRANCE

View details

christophe rochais

Professor

Université de Caen Normandie

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Patrick Dallemagne

Research Interests

Explore related searches

Contact this professor

Articles (10)

C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug

Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca<sup>2+</sup> Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation

Advances in prodrug design for Alzheimer’s disease: the state of the art

Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease

5-HT4R modulators: a patent landscape

Aminothiaindanone as an accessible scaffold for a three-point chemical diversity.

Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer’s Disease Treatment through Rigidification Strategy

Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment

Desirable drug–drug interactions or when a matter of concern becomes a renewed therapeutic strategy

First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease

Collaborators (12)

François-Xavier Toublet

Jana Sopkova-de Oliveira Santos

hélène MARTIN

Lhassane Ismaili

Serge Mignani

Marc Since

Krzysztof Jozwiak

Artur Wnorowski

Audrey DAVIS

Aurélie Malzert-Freon

thomas freret

christophe rochais

Make your next move.